Similarly, another anti-PD-1 antibody, pembrolizumab, has shown limited clinical benefit both as monotherapy and in combination with bevacizumab for recurrent GBM patients in phase I and II trials [32–34]. Here, PDCD1 is linked to glioblastoma.